Kleo Pharmaceuticals, Inc. announced that it has entered into a research collaboration with Green Cross LabCell (GCLC) to rapidly advance testing of both advanced technology platforms in combination as a potential therapy for COVID-19 patients. Earlier this year, Kleo received approval from the US FDA to proceed with an antibody recruiting molecule (ARM) NK cell combination therapy clinical trial for the treatment of newly diagnosed, multiple myeloma patients. The ARM in that trial targets the cell surface protein CD38 and uses autologous cytokine induced memory like (CIML) NK cells to kill tumor cells. Kleo's ARM technology platform can rapidly develop fully synthetic bifunctional molecules that redirect a patient's own antibodies for therapeutic effect. In the context of a COVID-19 therapeutic, the ARM has multiple proposed mechanisms of action. First, the ARM acts as a neutralizing antibody to block direct binding on the virus to human cells. Second, the ARM enlists immune effector cells to eliminate viral particles and/or infected cells. Third, the ARM can produce a long-term vaccination effect by activating and expanding immune memory cells.